Payment overview · 2025
General Payments
$533.70
24 reported records · 13 companies
Healthcare provider profile · identity verified
Mark Jerome Paradela, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATHENS, GA · NPI 1437131596
Verified facts
What the public records show
CMS Open Payments records show Mark Jerome Paradela, MD received $533.70 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.44 | 16.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.27 | 13.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.04 | 7.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.03 | 7.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.20 | 7.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.23 | 7.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.06 | 7.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.62 | 7.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.39 | 7.0% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $35.51 | 6.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.39 | 4.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.77 | 3.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.75 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $533.70 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $85.44 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $54.33 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.03 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.20 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.06 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.06 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
148 | 51 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 42 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 586 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 558 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 501 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 396 | 75 |
| Gabapentin | Gabapentin | 349 | 120 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 344 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 339 | 105 |
| Omeprazole | Omeprazole | 317 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 309 | 98 |
| Furosemide | Furosemide | 303 | 87 |
| Metformin Hcl | Metformin Hcl | 275 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 87 |
| Losartan Potassium | Losartan Potassium | 270 | 78 |
| Montelukast Sodium | Montelukast Sodium | 239 | 65 |
| Potassium Chloride | Potassium Chloride | 232 | 71 |
| Lisinopril | Lisinopril | 225 | 71 |
| Tizanidine Hcl | Tizanidine Hcl | 211 | 51 |
| Doxazosin Mesylate | Doxazosin Mesylate | 207 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 49 |
| Trazodone Hcl | Trazodone Hcl | 204 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 199 | 38 |
| Alprazolam | Alprazolam | 191 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 82 |
| Famotidine | Famotidine | 184 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 183 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 47 |
| Carvedilol | Carvedilol | 171 | 46 |
| Sertraline Hcl | Sertraline Hcl | 167 | 43 |
| Donepezil Hcl | Donepezil Hcl | 163 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 162 | 48 |
| Prednisone | Prednisone | 149 | 90 |
| Topiramate | Topiramate | 149 | 48 |
| Linzess | Linaclotide | 148 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 46 |
| Tramadol Hcl | Tramadol Hcl | 138 | 50 |
| Eliquis | Apixaban | 135 | 42 |
| Simvastatin | Simvastatin | 125 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 35 |
| Buspirone Hcl | Buspirone Hcl | 114 | 29 |
| Myrbetriq | Mirabegron | 114 | 24 |
| Memantine Hcl | Memantine Hcl | 110 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 27 |
| Ozempic | Semaglutide | 108 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 104 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 23 |
| Mirtazapine | Mirtazapine | 101 | 31 |
| Jardiance | Empagliflozin | 100 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 35 |
| Trulicity | Dulaglutide | 99 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 30 |
| Allopurinol | Allopurinol | 93 | 28 |
| Cefdinir | Cefdinir | 93 | 80 |
| Cephalexin | Cephalexin | 92 | 75 |
| Meloxicam | Meloxicam | 88 | 32 |
| Cefuroxime | Cefuroxime Axetil | 87 | 70 |
| Glipizide | Glipizide | 83 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 43 |
| Atenolol | Atenolol | 74 | 20 |
| Januvia | Sitagliptin Phosphate | 73 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 21 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 69 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 56 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 19 |
| Clonazepam | Clonazepam | 68 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 54 |
| Mounjaro | Tirzepatide | 66 | 14 |
| Clonidine Hcl | Clonidine Hcl | 65 | 19 |
| Alendronate Sodium | Alendronate Sodium | 64 | 18 |
| Bupropion Xl | Bupropion Hcl | 64 | 21 |
| Pregabalin | Pregabalin | 61 | 24 |
| Azithromycin | Azithromycin | 56 | 40 |
| Lorazepam | Lorazepam | 55 | 12 |
| Valsartan | Valsartan | 55 | 23 |
| Tradjenta | Linagliptin | 54 | 11 |
| Glimepiride | Glimepiride | 53 | 16 |
| Farxiga | Dapagliflozin Propanediol | 52 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 15 |
| Ibuprofen | Ibuprofen | 50 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 12 |
| Fenofibrate | Fenofibrate | 49 | 13 |
| Nystatin | Nystatin | 49 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 45 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 12 |
| Torsemide | Torsemide | 48 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 15 |
| Ezetimibe | Ezetimibe | 47 | 17 |
| Fluconazole | Fluconazole | 47 | 29 |
| Meclizine Hcl | Meclizine Hcl | 45 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 11 |
| Spironolactone | Spironolactone | 44 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 14 |
| Metformin Hcl Er | Metformin Hcl | 43 | 19 |
| Ranolazine Er | Ranolazine | 43 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 16 |
| Megestrol Acetate | Megestrol Acetate | 41 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 14 |
| Valacyclovir | Valacyclovir Hcl | 39 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 36 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 11 |
| Azelastine Hcl | Azelastine Hcl | 35 | 14 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Colchicine | Colchicine | 34 | 17 |
| Primidone | Primidone | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Lubiprostone | Lubiprostone | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 17 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | 13 |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | 11 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 12 |
| Dutasteride | Dutasteride | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 11 |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Naproxen | Naproxen | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $533.70 · 24 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, COMIRNATY, DAYBUE, Dexcom G6 Transmitter, EVENITY, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Rybelsus, TZIELD, UBRELVY, VRAYLAR, XHANCE, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error